American Ruihui Company has aroused heated discussion among the public. As an American pharmaceutical giant, who is Ruihui's partner in China? Let's take a look with Bian Xiao!
Ruihui cooperated with Kangxinuo to help produce meningitis vaccine.
In July 2020, Ruihui signed an agreement with vaccine manufacturer Kangxinuo to promote the latter meningitis vaccine in China; The vaccine has not been approved by the regulatory authorities. Subsequently, in September, the company invested US$ 200 million (S $268 million) in another biotechnology company in China, and obtained a 9.9% stake in the latter and its experimental cancer treatment drug authorization in the mainland market.
Pfizer and Peg Biomedical are committed to meeting the needs of patients in China.
202 1 12 13, Pfizer signed an agreement with Paige Biomedical (Suzhou) Co., Ltd. to authorize Paige to develop glucokinase activator (GKA) drugs. Shan, general manager of Pfizer's global innovative medical care in China, said that through this cooperation, Pfizer will take the urgent medical needs of patients in China as the starting point, select appropriate research and development projects, and jointly develop drugs needed by patients in China with powerful local partners.
Pfizer cooperates with Haier Bio, PICC P&C Insurance and Ali Health to help realize "Healthy China 2030".
In order to better improve the accessibility of disease prevention and vaccination services, Pfizer China signed a memorandum of strategic cooperation with Haier Bio and PICC P&C at the 4th China International Import Expo, and further cooperated with Ali Health. Pfizer will join hands with its partners to help realize "Healthy China 2030" through innovative cooperation.
The general manager of Haier Biomedical Vaccine Network said that the future cooperation between the two sides will mainly focus on three key themes. The three key themes are "enhancing the public awareness of infectious disease prevention and vaccination" and "improving the experience journey and service channels of key decision makers in vaccination and improving the accessibility of vaccination"; "Empower medical staff and optimize the ways and means of contacting with the public."
PICC P&C and Pfizer China signed a strategic cooperation agreement at China International Import Expo (CIIE) on 20021to give full play to their advantages in the field of public health. Based on the principles of voluntariness, fairness and honesty, the two sides will cooperate around the new model of "vaccine+insurance" to create innovative vaccine insurance services, diseases and vaccine science popularization.
Pfizer and Ali Health signed a memorandum of strategic cooperation in Beijing, and will continue to cooperate in drug traceability and smart medical care, and gradually explore in-depth research in drug safety and patient education. In addition, under the call of the national medical reform policy, the two sides will also train doctors for public welfare projects.
In the future, Pfizer will continue to join hands with start-up partners such as China Acceleration, Beibei Granule and 100 Medical to seek new and effective ways and continue to explore innovative digital solutions in the field of disease prevention.